Benzinga | Aug 24, 2020 07:34AM EDT

Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11

Ladenburg Thalmann analyst Robert LeBoyer initiates coverage on CNS Pharmaceuticals (NASDAQ:CNSP) with a Buy rating and announces Price Target of $11.